Martin Mackay

Type: Person
Name: Martin Mackay
First reported Jul 29 2014 - Updated Jul 29 2014 - 1 reports

Texan firm buys disaster recovery bods Neverfail

HP ProLiant Gen8: Integrated lifecycle automationUK business continuity specialist Neverfail has been acquired by US-based Artisan Infrastructure in a quiet and unannounced deal.Ex-Neverfail MD Martin Mackay said: ”I am not at liberty to give details ... [Published The Register - Jul 29 2014]
First reported Jul 25 2014 - Updated Jul 25 2014 - 1 reports

GLASGOW 2014: Commonwealth Games diaries - 25 July

The Glasgow Chamber of Commerce's Warm Up Breakfast event this morning will look at 'Glasgow: a City for Creative Business'. Speakers Martin Mackay of Clyde Gateway, Rufus Logan of BRE Scotland, Scott Simpson of Radiate, an integrated marketing communications ... [Published Meetpie - Jul 25 2014]
First reported Jul 24 2014 - Updated Jul 24 2014 - 1 reports

Alexion Pharmaceuticals' (ALXN) CEO Leonard Bell on Q2 2014 Results - Earnings Call Transcript

OperatorGood morning, and welcome to the Alexion Pharmaceuticals, Incorporated Second Quarter 2014 Results Conference Call. Today's call is being recorded.For opening remarks and introductions, I would like to turn the conference over to Mr. Irving Adler, ... [Published Seeking Alpha - Jul 24 2014]
First reported Jul 02 2014 - Updated Jul 02 2014 - 1 reports

Alexion and Cincinnati Children's Launch Rare Disease Innovation Fund

By a News Reporter-Staff News Editor at Biotech Week -- Alexion Pharmaceuticals, Inc. (Nasdaq:ALXN) and Cincinnati Children's Hospital Medical Center announced the establishment of a collaboration and fund for the advancement of research in rare disease. ... [Published HispanicBusiness.com - Jul 02 2014]
First reported Jul 02 2014 - Updated Jul 02 2014 - 1 reports

FDA Grants Orphan Drug Designation to Soliris eculizumab for the Treatment of Patients with Myasthenia Gravis MG

By a News Reporter-Staff News Editor at Biotech Week Alexion Pharmaceuticals (Nasdaq:ALXN) announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to Soliris (eculizumab) for the treatment of patients with ... [Published Pharmacy Choice - Jul 02 2014]
First reported Jun 27 2014 - Updated Jun 27 2014 - 1 reports

Conference Call Schedules, Disclosures, Partnerships, and Acquisitions - Analyst Notes on Pfizer, Covidien, UnitedHealth Group, Alexion and Abbott

/PRNewswire/ --Today, Analysts Review released its analysts' notes regarding Pfizer Inc. ( NYSE: PFE ), Covidien plc ( NYSE: COV ), UnitedHealth Group Inc. ( NYSE: UNH ), Alexion Pharmaceuticals, Inc. ( NASDAQ: ALXN ) and Abbott Laboratories ( NYSE: ABT ... [Published Securities Technology Monitor - Jun 27 2014]
First reported Jun 26 2014 - Updated Jun 26 2014 - 1 reports

ALEXION PHARMACEUTICALS : FDA Grants Orphan Drug Designation to Soliris® eculizumab for the Treatment of Patients with Myasthenia Gravis MG

By a News Reporter-Staff News Editor at Biotech Week -- Alexion Pharmaceuticals (Nasdaq:ALXN) announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to Soliris® (eculizumab) for the treatment of patients with ... [Published 4 Traders - Jun 26 2014]
First reported Jun 24 2014 - Updated Jun 24 2014 - 1 reports

ALEXION PHARMACEUTICALS : Gets FDA Orphan Drug Designation for Soliris (eculizumab) in Treatment of Patients with Myasthenia Gravis (MG)

Alexion Pharmaceuticals said that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to Soliris (eculizumab) for the treatment of patients with Myasthenia Gravis (MG), a rare, debilitating neurologic disorder caused ... [Published 4 Traders - Jun 24 2014]
First reported Jun 23 2014 - Updated Jun 23 2014 - 1 reports

Alexion and Cincinnati Children’s Launch Rare Disease Innovation Fund

Alexion Pharmaceuticals, Inc. (Nasdaq:ALXN) and Cincinnati Children ’sHospital Medical Center today announced the establishment of a collaboration and fund for the advancement of research in rare disease.Cincinnati Children’s is a recognized center of ... [Published BioPortfolio - Jun 23 2014]
First reported Feb 15 2014 - Updated Feb 15 2014 - 1 reports

Prothelia, University of Nevada sign agreements with Alexion to develop Laminin-111

Prothelia Incorporated, a privately held biotechnology company, and University of Nevada, Reno have entered into strategic agreements with Alexion for the development of Laminin-111, a patented experimental protein replacement therapy for merosin-deficient ... [Published PharmaBiz - Feb 15 2014]
First reported Feb 13 2014 - Updated Feb 14 2014 - 1 reports

Prothelia and the University of Nevada, Reno Enter Into Exclusive Strategic Agreements with Alexion for Catastrophic, Ultra-Rare Neuromuscular Disorder

MILFORD, Mass.The three parties have entered into a binding agreement wherein Alexion has an exclusive option to acquire privately-held Prothelia and license Laminin-111 directly from the University of Nevada, Reno"This partnership with Alexion represents ... [Published PR Newswire - Feb 13 2014]

Quotes

"collaborations between industry and academia are important to drive innovation for patients suffering from rare diseases and we look forward to working with cincinnati children's to advance our research programs, which are focused on developing life-transforming therapies for patients with devastating disorders" said Martin Mackay , Ph D , Executive Vice President and Global Head of ResearchResearch and Development at Alexion...
...which could lead to a life-threatening myasthenic crisis," said Martin Mackay, Ph D , Executive Vice President, Global Head of R&D at Alexion. "by specifically inhibiting the terminal complement pathway, which is believed to play a pivotal role in the pathophysiology of mg, we believe that eculizumab has the potential to help patients living with this devastating rare disorder."
"mdc1a is a disease that aligns very well with our passion to develop and deliver first-in-class drug candidates that have the potential to transform the lives of people suffering with devastating disorders that currently have no treatment options" said Martin Mackay, Ph D , executive vice president, head of Global Research & Development at Alexion...
...the risk of DGF, a benefit that may have positive implications for longer-term kidney function and clinical outcomes for patients," Mackay said. "in addition, a significant number of donor kidneys are reportedly never used and thus discarded each year due to the risk of poor outcomes associated with dgf, therefore reducing the risk of dgf may enable more patients to receive a kidney transplant." The company intends to start a single multinational DGF registration trial with Soliris later in 2014. Latest News

More Content

All (13) | News (13) | Reports (0) | Blogs (0) | Audio/Video (0) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
Texan firm buys disaster recovery bods Neverfail [Published The Register - Jul 29 2014]
GLASGOW 2014: Commonwealth Games diaries - 25 July [Published Meetpie - Jul 25 2014]
Alexion Pharmaceuticals' (ALXN) CEO Leonard Bel... [Published Seeking Alpha - Jul 24 2014]
Alexion and Cincinnati Children's Launch Rare D... [Published HispanicBusiness.com - Jul 02 2014]
FDA Grants Orphan Drug Designation to Soliris e... [Published Pharmacy Choice - Jul 02 2014]
Conference Call Schedules, Disclosures, Partner... [Published Securities Technology Monitor - Jun 27 2014]
ALEXION PHARMACEUTICALS : FDA Grants Orphan Dru... [Published 4 Traders - Jun 26 2014]
ALEXION PHARMACEUTICALS : Gets FDA Orphan Drug ... [Published 4 Traders - Jun 24 2014]
Alexion and Cincinnati Children’s Launch Rare D... [Published BioPortfolio - Jun 23 2014]
Prothelia, University of Nevada sign agreements... [Published PharmaBiz - Feb 15 2014]
Prothelia and the University of Nevada, Reno En... [Published PR Newswire - Feb 13 2014]
US FDA grants Alexion' Soliris orphan drug stat... [Published Pharmaceutical Business Review - Jan 22 2014]
Alexion's cPMP replacement therapy gets US FDA ... [Published PharmaBiz - Oct 28 2013]
1
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.